You may be surprised at who leads the world in cannabis consumption. On Jan. 31 Seedo released its “2018 Cannabis Price Index” which identified the cities with the most and least expensive cannabis, the cities with the most tax revenue potential and the cities with the highest and lowest consumption rates.
In total, 120 cities worldwide cities were examined, all with various legal statuses. We often assume the United States is the global leader in cannabis consumption, and it is, to some degree. But other nations, notably India and Pakistan, are also full of cannabis lovers and they are not far behind the United States in terms of cannabis consumption rates. New York City leads the globe in cannabis consumption, although the report had a few surprises. Citizens in New Delhi, India, for instance, consume more cannabis per year than in Los Angeles, California. Citizens in Cairo, Egypt, in addition, consume more cannabis per year than in London, U.K.
Below are the cities that consume the most cannabis per year:
- New York City, United States, 77.44 metric tons
- Karachi, Pakistan, 41.95 metric tons
- New Delhi, India, 38.26 metric tons
- Los Angeles, United States, 36.06 metric tons
- Cairo, Egypt, 32.59 metric tons
- Mumbai, India, 32.38 metric tons
- London, U.K., 31.4 metric tons
- Chicago, United States, 24.54 metric tons
- Moscow, Russia, 22.87 metric tons
- Toronto, Canada, 22.75 metric tons
Cannabis legality appears to have no effect on consumption rates. In Karachi and Cairo, cannabis is 100 percent illegal, and in London, only Sativex is recognized as having therapeutic value, yet these cities lead the world in cannabis consumption.
Missing from the list are cities from China, South Korea and Japan, where cannabis is noticeably less popular and less of a part of their cultures. This could also be explained by the soaring cost of cannabis in those countries. Tokyo tops the list for the most expensive cannabis, at an average of $32.66 USD per gram.
The numbers shed light on cannabis trends in countries such as India, where western media rarely touches.
Cannabis Survey Seeks Input from New Jersey Mayors
A survey put out by the New Jersey League of Municipalities (NJLM) and the Cannabis Advisory Group is seeking the input of state mayors regarding the newly legal cannabis industry in New Jersey.
“The purpose of this survey is to identify the most pressing challenges and concerns facing their communities in preparation for the sale of both medical and adult-use cannabis and help inform and guide our work with the State Cannabis Regulatory Commission,” said Mayor of Clinton, Janice Kovach, who is also the president of the NJLM.
The NJLM hopes to gather data to help them learn more about what challenges they may face as local government representatives. The survey asks about whether municipalities will be allowing cannabis businesses, and to what degree they will be allowing legal cannabis sales, grows or other facilities in their areas.
“It’s an exciting new landscape in New Jersey, but marijuana legalization also poses a lot of unknowns, particularly on the local level,” said Jacqueline Ferraro of the Cannabis Advisory Group. “To help ensure the industry’s success, we felt it was important to gather a comprehensive understanding of the concerns, questions and predispositions of our municipalities. By teaming up with the League, we hope to help policymakers, entrepreneurs and community members strategically address those issues that are most pressing as legalization moves forward.”
She claims that the plan “is to hear from all of our communities on the impact of recreational cannabis—especially what they want to see from the League and the Advisory Group as resources.”
“We are a diverse state of 565 municipalities and there is no one size fits all,” she added. “This survey will help guide the tools that need to be made available for informed decisions.” The survey will provide more insight about cannabis and what New Jersey can expect when it becomes officially legal on January 1, 2021.
Medical Cannabis Success in Three-Year-Old Prompts Legal Review
The family of a toddler with a rare form of epilepsy is asking for a legal review of cannabis oil in Norwich, England.
Three-year-old Charlie Hughes suffers from West syndrome, a condition that can cause him to experience up to 120 seizures every day. With the addition of a proper medical cannabis oil regimen, his parents Alison and Matt Hughes report that he now suffers from less than 20 seizures per day. According to The Guardian, the National Health Service (NHS) prescribed Charlie with a number of pharmaceutical drugs in the past that not only caused him to experience lethargy regularly, but did not effectively reduce his seizures.
Ever since Charlie began taking medical cannabis, he has become more vibrant and alive than ever before. “Charlie is happier, more alert, far more vocal, constantly babbling and takes an interest in his toys,” Matt told The Guardian. “He can feed himself and loves nothing more than some rough and tumble with me. He’s come alive again. No one knows definitively what effect all those anti-epileptic drugs in combination with each other have on the development of the brain. If he wasn’t asleep or completely zonked out, he was just seizing. Cannabis has massively improved his general wellbeing.”
The Hughes family has found its medicine of choice, but it is a complicated process due to the fact that although medical cannabis oil is legal, it still remains unlicensed in England. The family is forced to source Charlie’s medicine privately, because the NHS will not prescribe cannabis to them directly. Similar instances for other families have caused hardships and stress, so the Hughes are taking the issue to court.
Having seen the impressive results, Matt has partnered with the National Institute for Health and Care Excellence (NICE) for legal aid. As of July 30, a court justice granted permission to call for a formal review due to reasons such as “alleged inadequate consultation” and “alleged failure to take into account relevant considerations,” as stated in court documents.
Professionals such as Professor Harry Sumnall from Liverpool John Moores University believe that a formal review could help the NHS open up the conversation to prescribing medical cannabis in the future. “Nice has argued that the guidance is clear and that there is nothing stopping the NHS from currently prescribing cannabis-based products. Perhaps a successful outcome for the claimant will lead to clarity over this or generate momentum for prescribing in the claimant’s particular case,” Sumnall said.
NICE has provided the NHS with 35 days to contest this claim, which will conclude at the end of August.
Creating partnerships can prove to be beneficial in any industry, and the cannabis industry is no exception. When two institutions have something of value to offer, they often can accomplish more together. The researchers at Washington State University (WSU) and the team at the Biopharmaceutical Research Company (BRC) no doubt hope to realize this kind of successful partnership. Their alliance was announced in early November, in which BRC will provide analytical services to researchers at the university. The university’s researchers will also have better access to cannabis as a result of the partnership.
As a pharmaceutical manufacturer and analytics company, BRC was built by its founders to provide a solution to the lack of certified cannabis needed for scientific research. The team at BRC is comprised of horticulture experts, academics, pharmaceutical manufacturers and much more. The company website states, “We take our responsibility to provide the scientific community with superior quality cannabis seriously.”
The chair of the WSU Collaborative for Cannabis Policy, Research and Outreach, Michael McDonell shared with CULTURE, “We would like to have the ability to obtain cannabis for research that allows us to conduct animal and human research related to health and public safety. Once BRC obtains a schedule one license to grow cannabis for research, we are hoping we will be able to obtain cannabis for research from BRC.”
The university hopes to expand its work with cannabis once the BRC receives a license to cultivate cannabis. “Our ongoing work is primarily related to animal research focused on the impact of cannabis on health. We are also conducting human research, but none that requires a Schedule 1 license,” McDonell explained.
The research team at WSU has already been allowed cannabis possession by the federal government. However, other difficulties in conducting research linger. Despite the partnership McDonell said the “difficulties remain the same,” but the alliance gives possibility for future growth in research.
“We would like to have the ability to obtain cannabis for research that allows us to conduct animal and human research related to health and public safety.”
Traditionally, cannabis research has been met with resistance and multiple legal obstacles. It was only in August of this year that U.S. Department of Justice decided to expand the 2016 program by allowing other cannabis producers to obtain licensing to supply cannabis for research. Before this decision, those looking to study cannabis could only use product from one federally approved producer. As demand for “research cannabis” continues to climb, the federal government needs to meet the demand with better policies and accessibility for research.
Yet the question remains, why is it still so difficult to obtain cannabis for necessary and beneficial scientific research? Although recreational cannabis is not yet accepted at the federal level, it is hard to deny that more studies on cannabis would provide various benefits to public health.
While advocates, patients, caretakers and recreational consumers of cannabis wait for these necessary changes to cannabis research accessibility, BRC is currently looking to analyze, import and one day grow cannabis for itself. The company is already registered with the Drug Enforcement Administration to conduct research on cannabis derived products. Right now, BRC waits for the approval of the federal government as they have already filed for a cultivation permit. Products produced by BRC could then be used for federally approved studies.
Europe Cannabis Testing Market Expected to Reach $770 Million By 2027
Retired Jamaican Sprinter Opens Medical Cannabis Dispensary
Nebraska Senator Introduces Medical Cannabis Bill
Colorado Cannabis Sales Top $2 Billion in 2020
Cannabis Consumption Could Affect Fertility Rates
Michigan Prosecutor Will No Longer Pursue Cannabis Cases
Strain of the Week: Midnite
DEA Could Issue More Cultivation Licenses Next Year
Cannabis Delivery Approved for Aurora, Colorado
Study Evaluates Cannabis Consumers’ Understanding of Smoking Risks
New Jersey Governor Seeks to Elevate Punishments for Youth Cannabis Consumption
Texas Officials Already Filing 2021 Cannabis Bills
Pre-Christmas Cannabis Sales Could Hit $400 Million
Rand Paul Brings up Edibles in Festivus Grievances
A Look at CULTURE’s 4/21 Party!
Happy Hanukkah !
Cannabis Use in the U.S. Doubled Over a Recent 12 Year Time Span | CULTUREtv
5 Things To Know about the New Canna-Friendly Travel Policy at Portland International
See the Cannabis Commercial Pulled from Denver Airwaves Before its Big Debut
China’s financial crisis is having an unexpected effect on the cannabis industry
Was cannabis the most popular legal inebriant in Colorado in 2014?
Strain Reviews2 years ago
Strain of the Week: Gushers
Strain Reviews10 months ago
Concentrate of the Week: Blueberry Kush CO2 Crumble
Strain Reviews4 years ago
Dirty Sprite by Blackleaf
Strain Reviews3 years ago
Strain Reviews4 years ago
Strain Reviews4 years ago
imported7 years ago
Featured Stories3 years ago
Cannabis-Infused Edibles Laws: A State-By-State Breakdown